Alnylam Pharmaceuticals (ALNY) Deferred Taxes (2009 - 2026)
Alnylam Pharmaceuticals (ALNY) reported Deferred Taxes of $9.3 million for Q1 2026, down 3.41% on a YoY basis from $9.6 million in Q1 2025, and up 134.27% quarter-over-quarter from -$27.2 million in Q4 2025.
Alnylam Pharmaceuticals (ALNY) Deferred Taxes (2009 - 2026) Analysis & Trends
Alnylam Pharmaceuticals has reported Deferred Taxes for 5 years, with the latest figure at $9.3 million in Q1 2026.
- For the quarter ending Q1 2026, Deferred Taxes fell 3.41% year-over-year to $9.3 million; the trailing twelve-month figure through Mar 2026 stood at -$2.5 million (up 97.41% YoY), and the FY2025 full-year result was -$2.2 million, up 97.94% from the prior year.
- Deferred Taxes for Q1 2026 stood at $9.3 million, up from -$27.2 million in the prior quarter.
- The five-year high for Deferred Taxes was $9.7 million in Q2 2025, with the low at -$107.4 million in Q4 2024.
- Historically, Deferred Taxes has averaged -$11.1 million across 3 years, with a median of $454000.0 in 2024.
- Annual changes were most pronounced in 2025 — Deferred Taxes jumped 3534.36% — and 2026, when it fell 3.41%.
- Alnylam Pharmaceuticals' Deferred Taxes stood at -$107.4 million in 2024, then jumped by 74.7% to -$27.2 million in 2025, then jumped by 134.27% to $9.3 million in 2026.
- The last three Deferred Taxes figures came in at $9.3 million (Q1 2026), -$27.2 million (Q4 2025), and $5.6 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Deferred Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -859,000.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | -65.30 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Alnylam Pharmaceuticals | 37.04 Bn | 34.03 Bn | 959.66 Mn | 9.31 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 9.31 Mn |
| Dec 31, 2025 | -27.17 Mn |
| Sep 30, 2025 | 5.60 Mn |
| Jun 30, 2025 | 9.74 Mn |
| Mar 31, 2025 | 9.64 Mn |
| Dec 31, 2024 | -107.39 Mn |
| Sep 30, 2024 | -163,000.00 |
| Jun 30, 2024 | 340,000.00 |
| Mar 31, 2024 | 454,000.00 |
| Dec 31, 2010 | 10.88 Mn |
| Sep 30, 2010 | 83,000.00 |
| Jun 30, 2010 | -85,000.00 |
| Mar 31, 2010 | -131,000.00 |
| Dec 31, 2009 | -5.19 Mn |
| Sep 30, 2009 | 281,000.00 |